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Type 1 iodothyronine deiodinase (D1), a selenoenzyme that catalyzes the bioactivation of thyroid
hormone, is expressed mainly in the liver. Its expression and activity are modulated by several
factors, but the precisemechanism of its transcriptional regulation remains unclear. In the present
study, we have analyzed the promoter of human D1 gene (hDIO1) to identify factors that preva-
lently increase D1 activity in the human liver. Deletion and mutation analyses demonstrated that
a forkhead box (FOX)A binding site and an E-box sitewithin the region between nucleotides187
and132 are important for hDIO1 promoter activity in the liver. EMSA demonstrated that FOXA1
and FOXA2 specifically bind to the FOXA binding site and that upstream stimulatory factor (USF)
specifically binds to the E-box element. Overexpression of FOXA2 decreased hDIO1 promoter
activity, and short interfering RNA-mediated knockdown of FOXA2 increased the expression of
hDIO1 mRNA. In contrast, overexpression of USF1/2 increased hDIO1 promoter activity. Short in-
terfering RNA-mediated knockdown of FOXA1 decreased the expression of hDIO1 mRNA, but
knockdownofboth FOXA1andFOXA2 restored it. The responseof thehDIO1promoter toUSFwas
greatly attenuated in the absence of FOXA1. Taken together, these results indicate that a balance
of FOXA1 and FOXA2 expression modulates hDIO1 expression in the liver. (Endocrinology 153:
492–500, 2012)
Thyroid hormone activation and inactivation are me-diated by three selenoenzymes, type 1 iodothyronine
deiodinase (D1), D2, and D3. D1 and D2 catalyze the
conversion of T4 to T3 via removal of outerring iodine (1).
The human D1 gene (hDIO1) is expressed in the liver,
kidney, thyroid, and pituitary (2). The D2 gene is ex-
pressed in the central nervous system, pituitary, heart, and
skeletalmuscle, but it is absent in the liver (1). TheD3gene
is expressed in the central nervous system and placenta,
and it is involved in thyroid hormone inactivation by me-
diating the removal of innerring iodine. Unlike D2, D1
activity is considered to be regulated predominantly at the
pretranslational level. The expression and activity of D1
are modulated by a variety of factors. T3 induces the ex-
pression of hDIO1 via two thyroid hormone responsive
elements within its promoter (3), and nuclear factor B
induced by TNF inhibits the T3-dependent induction of
D1 (4). However, the precise mechanism of the transcrip-
tional regulation of hDIO1 expression remains unclear.
In this study, we sought to identify factors that in-
creasedD1activity in the liver, amainorgan that expresses
hDIO1. We assessed the promoter activity of the 5-kb
5-flanking regionofhDIO1 and characterized regulatory
element-binding proteins within this region. In this study,
we identify responsive elements for the forkhead box
(FOX) transcription factors FOXA1/FOXA2 and the ba-
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sic/helix-loop-helix-leucine zipper transcription factor
upstream stimulatory factor (USF), and we show that
FOXA1, FOXA2, andUSFall participate in the regulation
of hDIO1. We also show that FOXA1 is required for the
activation of the hDIO1 promoter by USF and that
FOXA2represses the transcriptionofhDIO1anddisrupts
the interaction of USF with FOXA1 by occupying the
FOXA binding site. Collectively, these results demon-
strate that FOXA1 and FOXA2 display opposing activity
in the regulation of hDIO1 expression in the liver.
Materials and Methods
Cell culture
The human liver carcinoma cell line HepG2 was obtained
from American Type Culture Collection (Manassas, VA) and
cultured in MEM (Life Technologies, Carlsbad, CA) with 0.1
mM nonessential amino acid solution (Life Technologies), 1 mM
sodium pyruvate (Life Technologies), 100 U/ml penicillin, 100
g/ml streptomycin, and 0.25 g/ml amphotericin B supple-
mented with 10% fetal bovine serum (Sigma-Aldrich, St. Louis,
MO) at 37 C in a humidified atmosphere containing 5% CO2.
TSA 201 cells, a clone of human embryonic kidney 293 cells (5),
were cultured inDMEM(Life Technologies) with 100U/ml pen-
icillin, 100 g/ml streptomycin, and 0.25 g/ml amphotericin B
supplemented with 10% fetal bovine serum at 37 C in a humid-
ified atmosphere containing 5% CO2.
Plasmid construction
Deletion mutants of the 5-flanking regions of hDIO1
(4949,2023,343,187,150,131, and103/4, the
translational start sitewas set at1)werepreparedbyPCRusing
human genomic DNA from leukocytes as a template. The re-
sulting PCR products were subcloned into EcoRV orKpnI/Hin-
dIII-digested pGL4.10 (Promega, Madison, WI) to create a fu-
sion with the luciferase gene (4949, 2023, 343, 187,
150, 131, and 103/4 hDIO1-Luc). The PCR primers,
containingEcoRV,KpnI, orHindIII linker, are listed in Table 1.
The correct orientation of these deletion mutant constructs was
confirmed by sequencing.
Mutations were created using the QuikChange Site-Directed
Mutagenesis kit (Stratagene, La Jolla, CA), according to the
manufacturer’s instruction; 187/4 and 150/4 hDIO1-
Luc were used as templates. For mutagenesis, the sequences of
the FOXA binding element and E-box were specified in figure 3
below.Mutated constructs were isolated from each reaction and
verified by sequencing.
Plasmids expressing cDNA for FOXA2 and USF1, pF1KB7038
and pF1KB8339, respectively, were generated by Kazusa DNA
Research Institute (Chiba, Japan) and purchased from Promega.
These plasmidswere digestedwith SgfI andPmeI, and cDNA for
FOXA2 and USF1 were ligated into the SgfI/PmeI-digested
pF4A CMV Flexi vector (Promega), which uses the human
cytomegalovirus intermediate-early enhancer/promoter to al-
low constitutive protein expression at native levels in mam-
malian cells. The open reading frame of human USF2 was
generated by PCR using HeLa cell cDNA as a template. The
PCR primers containing SgfI or PmeI linker are listed in Table
1. The PCR product was digested with SgfI and PmeI, cloned
into the SgfI/PmeI-digested pF4A CMV Flexi vector, and ver-
ified by sequencing.
Transient transfection and luciferase assay
HepG2 and TSA 201 cells were plated at 1.5–2  105 and
0.5–1  105 cells/well in 24-well tissue culture plates, respec-
tively. Cells weremaintained in 0.5ml of antibiotic-freemedium
for 1 d before transfection. Transient transfections were per-
formed using the Lipofectamine LTX reagent (Life Technolo-
gies) for HepG2 cells and the Lipofectamine 2000 reagent (Life
Technologies) for TSA201 cells according to themanufacturer’s
instruction. In HepG2 cells, transfections included 500 ng of
experimental reporter constructs and 25 ng of pGL4.74, which
contained the cDNAencodingRenilla luciferase (Promega) as an
internal control for transfection efficiency. In TSA 201 cells,
transfections included 100 ng of experimental reporter con-
structs and 5 ng of pGL4.74. In the experiments with plasmids
expressing FOXA2 and/or USF, total amount of plasmid DNA
was kept constant by adding the corresponding amount of pF4A
without a cDNA insert. After transfection, cells were grown in
antibiotic-free medium and harvested after 48 h. Luciferase ac-
tivity was determined using the Dual-Luciferase Reporter Assay
System (Promega), and luminescence was measured by a 2030
ARVOXmultilabel reader (PerkinElmer,Waltham,MA).Firefly
luciferase activitywas normalized toRenilla luciferase activity in
each well to control for transfection efficiency.
Computational analysis of the putative
transcription factor binding sites
The putative transcription factor binding sites on the 5-
flanking region of hDIO1 were identified by computational
TABLE 1. Oligonucleotides used in plasmid construction and RT-PCR
Forward primer (5-3) Reverse primer (5-3) Accession no.
Plusmid construction
4949/4 hdio1-Luc GGGGATATCGCAGGTGCAGCCTAGAGATGTAACG CCCAAGCTTGGCAAAGCCAGAGTAAGCTC AL031427
2023/4 hdio1-Luc CGGGGTACCACACTTCCATTCCAGTTACAG CCCAAGCTTGGCAAAGCCAGAGTAAGCTC AL031427
343/4 hdio1-Luc CGGGGTACCGAGAGAGCATCTAACAGGTTC CCCAAGCTTGGCAAAGCCAGAGTAAGCTC AL031427
187/4 hdio1-Luc CGGGGTACCGACCTTTGTGCACCTGGTTAG CCCAAGCTTGGCAAAGCCAGAGTAAGCTC AL031427
150/4 hdio1-Luc CGGGGTACCGACAGAAAGGCAAACATCTTC CCCAAGCTTGGCAAAGCCAGAGTAAGCTC AL031427
131/4 hdio1-Luc CGGGGTACCTCTGACCTGACTCCTTCCCCTG CCCAAGCTTGGCAAAGCCAGAGTAAGCTC AL031427
103/4 hdio1-Luc CGGGGTACCGGTTGGCTGCTCCTACCCTGC CCCAAGCTTGGCAAAGCCAGAGTAAGCTC AL031427
pF4A-USF2 AGCAGCGATCGCCATGGACATGCTGGACCCGGGTCTGGA CGAGGTTTAAACCTGCCGGGTGCCCTCGCCCA NM_003367
RT-PCR
hDIO1 CAGAGTCAAGCGGAACATCC CCGTTGGTCACCTAGAATTG NM_000792
Cyclophilin A GCACTGGAGAGAAAGGATTTGG CAGCAATGGTGATCTTCTTGC NM_021130
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analysis using TFSEARCH databases (http://www.cbrc.jp/
research/db/TFSEARCHJ.html), based on the TRANSFAC da-
tabases (6).
RNA isolation, RT-PCR, and quantitative PCR
TotalRNAwas extracted fromHepG2cells using theRNeasy
Plus Mini kit (QIAGEN, Valencia, CA) according to the manu-
facturer’s instruction. One microgram of total RNAwas reverse
transcribed with random hexamers using a First-strand cDNA
Synthesis kit (GE Healthcare UK Ltd., Buckinghamshire, UK)
according to the manufacturer’s instruction. The resulting
cDNA were diluted 1:10 and subjected to PCR amplification
with 0.5 mM each of the sense and antisense primers and 0.5 U
of AmpliTaq Gold DNA polymerase (Life Technologies). The
PCR primers used for hDIO1 and human cyclophilin A gene are
indicated in Table 1. The PCR conditions were 40 cycles of de-
naturation for 1 min at 95 C, annealing for 1 min at 52 C, and
extension for 1 min at 72 C. The PCR products were electro-
phoresed in 2% agarose gels.
Quantitative PCR reactions were performed, recorded,
and analyzed using TaqMan Gene Expression Assays with
StepOnePlus real-time PCR system (Life Technologies). The
probe and primers were Hs00270129_m1 (human FOXA1),
Hs00232764_m1 (human FOXA2), and Hs00174944_m1
(hDIO1) and purchased from Life Technologies. Diluted
cDNAwere amplified using the following conditions: 50 C for
2 min, 95 C for 10 min, and 40 cycles of 95 C for 15 sec and
60 C for 1 min, followed by continuous incubation at 25 C.
Expression levels of FOXA1, FOXA2, and hDIO1 were nor-
malized to cyclophilin A to compensate for variations in input
RNA.
Preparation of cell extracts and EMSA
Nuclear extracts were prepared from HepG2 cells using the
Nuclear Extract kit (Active Motif, Carlsbad, CA), according to
the manufacturer’s instruction. EMSA were conducted using a
LightShift chemiluminescent EMSA kit (Thermo Fisher Scien-
tific, Rockford, IL)with slightmodifications of the originalman-
ufacturer’s instruction. Oligonucleotides 3-end labeled with bi-
otin were synthesized (Life Technologies) and annealed to
generate double-stranded oligonucleotide probes. Two hundred
femtomoles of oligonucleotide probe were incubated with
10–15 g of nuclear protein and 0.5 g of poly (dI-dC) in the
presence or absence of competing oligonucleotide in 10 bind-
ing buffer [containing 100 mM Tris, 500 mM KCl, and 10 mM
dithiothreitol (pH 7.5)] and 75 mM KCl, and 5% glycerol was
added to solutions containing probes with an E-box element.
After a 30-min incubation at room temperature, DNA-protein
complexes were separated by electrophoresis on a 6% DNA re-
tardation gel (Life Technologies) at 4 C in 0.5 Tris-borate,
EDTA buffer [containing 89 mM Tris-borate and 2 mM EDTA
(pH 8.0)]. For supershift assays, binding reactions were incu-
bated for 45min at room temperaturewith antibodies before the
addition of labeled probes. The antibodies used in the supershift
assayswere as follows: 1l (200g/0.1ml) ofUSF1 (sc-8983X),
USF2 (sc-861X), E47 (sc-763X), FOXA1 (sc-6553X), FOXA2
(sc-6554X), and FOXA3 (sc-5361X) and 5l (200g/0.5ml) of
normal goat andnormal rabbit IgG, and allwere purchased from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). After electro-
phoresis, samples were transferred onto nylon membranes and
fixed by UV irradiation. Biotinylated DNAwas detected using a
Fujix Lumino-image analyzer (LAS-1000; Fuji Photo Film Co.,
Ltd., Tokyo, Japan).
Transfection of short interfering RNA (siRNA)
An aliquot of 6 pmol siRNA specific for FOXA1 and/or
FOXA2 (Stealth Select RNAi, Life Technologies) or a negative
control siRNA (Stealth RNAi Negative Control, Life Technol-
ogies) was transfected into HepG2 cells using the Lipofectamine
RNAiMax reagent (Life Technologies) by reverse transfection
according to the manufacturer’s instruction. After transfection,
HepG2 cells were plated at 1.5–2  105 cells/well in 24-well
tissue culture plates and maintained in 0.5 ml of antibiotic-free
medium for 24–48 h. mRNA extraction and analysis were per-
formed as described above.
Statistics
The data represent the mean  SEM and were obtained from
at least three separate experiments, each performed in triplicate.
Statistical analyses were performed to examine the significance
of differences among the results using unpaired t test or ANOVA
followed by Student-Newman-Keuls test or Dunnett’s test.
Results
Functional analysis of the 5-flanking region of the
hDIO1 gene
To identify regionswithin the promoter regionofhDIO1
important for regulating its expression,a seriesof5-deletion
constructswas subcloned into the pGL4.10 vector and tran-
siently transfected into HepG2 and TSA 201 cells (Fig. 1A).
In both HepG2 and TSA 201 cells, luciferase activity in-
creased by deletion of nucleotides 150 to 131 and de-
creased after deletion of 131 to 103. Among the tested
constructs, the luciferaseactivityproducedby transfectionof
150/4 hDIO1-Luc was specifically and markedly de-
creased inHepG2 cells. Additionally, more pronounced dif-
ferenceswere seenbetween the activity of150/4hDIO1-
Luc and 131/4 hDIO1-Luc in HepG2 cells compared
withTSA201cells. Inaddition, luciferase activitywasmark-
edly increasedbydeletingtheregionfrom343to187and
decreased after deletion of 187 to 150 only in HepG2
cells. Taken together, these results indicate that the region
between nucleotides 187 and 132 is important for
hDIO1 promoter function in HepG2 cells. To confirm the
expression of hDIO1, we performed RT-PCR using total
RNA isolated from HepG2 and TSA 201 cells, a liver and
kidney cell line, respectively. As shown in Fig. 1B, although
there was a difference in the degree of gene expression,
hDIO1was expressed in both cell lines; this was consistent
with a previous report examining hDIO1 tissue distribution
(2). Additionally, multiple PCR products were detected, be-
cause there are several alternative splice variants of hDIO1
(7). These results indicate that there may exist a sequence
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essential for liver-specific expression of hDIO1 within the
187to132regionof itspromoter.Acomputationalanal-
ysis of this region revealed the presence of a consensusE-box
sitebetweennucleotides187and151andaFOXAbind-
ing site between nucleotides150 and132 (Fig. 1C).
Promoter activity associated with the FOXA
binding site and the E-box
Tobetter understand the contributionof theFOXAbind-
ing site and the E-box on the expression of hDIO1 in liver-
derivedHepG2 cells, we examined luciferase activity in cells
transfected with wild-type (WT) or mutated hDIO1 pro-
moter constructs. In HepG2 cells, luciferase activity was in-
creased2-foldbymutating theFOXAbinding sitewhencells
weretransfectedwitha150/4hDIO1-Lucconstruct (Fig.
2A). In addition, when cells were transfected with a
187/4 hDIO1-Luc construct, luciferase activity was
nearly completely lost by destruction of the E-box, and mu-
tation of the FOXA binding site caused a decrease in lu-
ciferase activity by 50% (Fig. 2B). In TSA 201 cells trans-
fected with 187/4 hDIO1-Luc, luciferase activity was
almost completely abolished by mutation of the E-box, but
mutation of the FOXA binding site in both 187/4
hDIO1-Luc and150/4 hDIO1-Luc did not significantly
affect luciferase activity (Fig. 2). Thus, the E-box present
within the hDIO1 promoter is required
for the enhancer activity in both liver-
and kidney-derived cells, but the FOXA
binding site exhibits liver-specific en-
hancer and repressor activity.
Binding of FOXA1/FOXA2 to the
FOXA binding site and USF to
the E-box
To determine the transcription fac-
tors that bind to these elements in the
promoter of hDIO1 inHepG2 cells, we
performed EMSA using oligonucleo-
tides with the FOXA binding site and
the E-box. Incubation of HepG2 cell
extracts with oligonucleotides contain-
ing the FOXA binding site (Fig. 3A,
WT-F) led to the formation of several
DNA/protein complexes (Fig. 3B, lane
2). Formation of one of these com-
plexeswas inhibitedby incubationwith
excessWT-F, but not mutated oligonu-
cleotide (MUT)-F, demonstrating the
specificity of this complex (Fig. 3B,
lanes 3–6). Additionally, the complex
was supershifted by addition of anti-
FOXA1 and anti-FOXA2 antibodies
(Fig. 3B, lanes 7 and 8). However, an
antibody specific for FOXA3, which binds an identical
sequence, or normal goat IgG did not disrupt complex
formation (Fig. 3B, lanes 9 and 10). These results suggest
that the putative FOXA binding site is specifically bound
by FOXA1 or FOXA2. We next examined binding to the








































FIG. 1. Liver-specific changes in hDIO1 promoter activity. A, A series of 5-deletion constructs
of the hDIO1 promoter were transiently transfected into HepG2 or TSA 201 cells. Promoter
activity was normalized to Renilla luciferase activity and expressed as the relative activity to
promoterless pGL4.10. Statistical significance was determined by ANOVA followed by
Student-Newman-Keuls test. *, P  0.05; **, P  0.01. N.S., Not significant. B, RT-PCR
analysis of hDIO1 expression. Electrophoretic analysis of RT-PCR products using total RNA
from HepG2 and TSA 201 cells was performed. The arrows and arrowhead correspond to the
RT-PCR products using total RNA from HepG2 and TSA 201 cells, respectively. Cyclophilin A
was used as a positive control. C, The nucleotide sequences of the 5-flanking region of
hDIO1 are shown. The translational start site was set at 1. Underlined sequences indicate
putative binding sites for transcription factors. Consensus sequences of E-box site and FOXA
binding site are shown at the bottom. Abbreviations for nucleotides: W (A or T), K (G or T), Y
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FIG. 2. Changes in hDIO1 promoter activity by FOXA binding site and
E-box. Schematic diagram in the left of each figure representing WT
and site-specific mutations of the hDIO1 promoter, introduced into the
upstream region of the luciferase gene. A cross represents the site-
specific mutation of the putative FOXA binding site or E-box. Each
construct was transiently transfected into HepG2 or TSA 201 cells.
Promoter activity was normalized to Renilla luciferase activity and
expressed as the relative activity to promoterless pGL4.10. Statistical
significance was determined by unpaired t test (A) or ANOVA followed
by Dunnett’s test (B). **, P  0.01. N.S., Not significant.
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incubation of HepG2 cell extracts with an appropriate
oligonucleotide (Fig. 3A,WT-E, andC, lane2). Formation
of one of these complexes was inhibited by incubating
with an excess ofWT-Eand theE-box fromhumanghrelin
gene (8) but not by amutant oligonucleotideMUT-E (Fig.
3C, lanes 3–8). Computational analysis predicted that the
putative E-box site binds the basic/helix-loop-helix-leu-
cine zipper transcription factorUSF, and to investigate this
hypothesis, a supershift assay was performed using anti-
bodies specific forUSF1 andUSF2.Addition of antibodies
specific for USF1 and USF2 completely inhibited complex
formation (Fig. 3D, lanes 7 and 8). However, incubation
with an antibody against E47, a protein that binds a sim-
ilar E-box sequence, or normal rabbit IgG did not disrupt
complex formation (Fig. 3D, lanes 9 and10). These results
suggest that USF1/USF2 bind the putative E-box, and this
complex likely contains a USF1/USF2 heterodimer. Col-
lectively, FOXA1, FOXA2, and USF likely participate in
the regulation of hDIO1 expression.
Effect of overexpression of FOXA2 or USF on
hDIO1 promoter activity
To determine whether FOXA and USF have the poten-
tial to affect the activity of the hDIO1 promoter in liver
cells, a 187/4 hDIO1-Luc construct was transiently
transfected into HepG2 cells along with increasing
amounts of either a FOXA2 or USF expression plasmid.
The luciferaseactivitydecreased inadose-dependentman-
ner by cotransfection of the FOXA2 expression plasmid
with 187/4 hDIO1-Luc (Fig. 4A). In contrast, lu-
ciferase activity increased dose dependently by the
cotransfection of the USF1 or USF2 expression plasmid,
and overexpression of USF2 consistently led to greater
hDIO1 promoter activity than expression of USF1 alone
(Fig. 4B). Thus, transcription of hDIO1 is negatively reg-
ulated by FOXA2 and positively regulated by USF. Al-
thoughwe transiently transfected a187/4 hDIO1-Luc
construct intoHepG2 cells alongwith increasing amounts
of a FOXA1 expression plasmid, we could not obtain ap-
propriate data, indicating that the FOXA1 expression
plasmid we used did not function in our experimental sys-
tem for unknown reason.
RNA interference
Next, we determined the effects of FOXAon the native
hDIO1 promoter using siRNA-mediated knockdown of


















































U1 U2 E47 C
Free probe
D
FIG. 3. Specific binding of the transcription factors within the 187 and 132 region in the hDIO1 promoter using nuclear proteins from HepG2
cells. Panel A, Sequences of the double-stranded oligonucleotides used in EMSA. WT-F, WT hDIO1 sequence identical to the 153 to 125
region, containing the FOXA binding site at 143 to 132. MUT-F contains a mutated FOXA binding site. WT-E, WT hDIO1 sequence identical to
the 187 to 159 region, containing the E-box at 177 to 172. MUT-E contains a mutated E-box. Each putative binding site is underlined; the
mutated base pairs are indicated by italic letters. Panel B, Oligonucleotide WT-F was used as the probe for EMSA either without competitor (lane 2)
or in the presence of 50- and 100-fold molar excesses of unlabeled WT-F (lanes 3 and 4, respectively) or MUT-F (lanes 5 and 6, respectively). The
specific complex formed from HepG2 cell nuclear extract and WT-F is indicated by an arrowhead. Supershift assay experiments were performed
using antibody against FOXA1 (F1; lane 7), FOXA2 (F2; lane 8), or FOXA3 (F3; lane 9) and normal goat IgG (C; lane 10). Panel C, Oligonucleotide
WT-E was used as the probe for EMSA either without competitor (lane 2) or in the presence of 50- and 100-fold molar excesses of unlabeled WT-E
(lanes 3 and 4, respectively), MUT-E (lanes 5 and 6, respectively), or 100-fold molar excesses of unlabeled E-box from the human ghrelin gene [E2
and E3 (in Ref. 8); lanes 7 and 8, respectively]. The specific complex formed from HepG2 cell nuclear extract and WT-E is indicated by an
arrowhead. D, Supershift assay experiments were performed using antibody against USF1 (U1; lane 7), USF2 (U2; lane 8), or E47 (E47; lane 9) and
normal rabbit IgG (C; lane 10). C, Negative control (normal goat and normal rabbit IgG).
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down of FOXA1 decreased the expression of hDIO1
mRNA, and knockdown of FOXA2 increased the expres-
sion level of hDIO1mRNA. FOXA1 and FOXA2 did not
affect each other’s expression by knockdownof them (Fig.
5, A and B). In addition, when both FOXA1 and FOXA2
were knocked down simultaneously, no change in the ex-
pression of hDIO1 mRNA was seen (Fig. 5C). Thus,
hDIO1 expression is positively regulated by FOXA1 and
negatively regulatedbyFOXA2, andFOXA1andFOXA2
interact with each other to regulate hDIO1 expression.
Interaction between FOXA and USF in the
activation of the hDIO1 promoter
Transcription factors frequently interact to coordi-
nately regulate gene expression, and we first wished to
determine whether the FOXA binding site and the E-box
present in thehDIO1promoter interact.Wecotransfected
a WT or mutated 187/4 hDIO1-Luc construct and
USF expression plasmids into HepG2 cells. When the
FOXAbinding sitewasmutated, the transcription activity
of the hDIO1 promoter in the presence of transfectedUSF
was attenuated (Fig. 6A). Thus, activation of the hDIO1
promoter by USF depends on the presence of a functional
FOXA binding site. Next, we investigated the effects of
FOXA on the response of the hDIO1 promoter to USF.
We knocked down the expression of FOXA and cotrans-
fected a 187/4 hDIO1-Luc construct along with USF
expression plasmids into HepG2 cells. As shown in Fig.
6B, the transcription activity of the hDIO1 promoter was
attenuated by knockdown of FOXA1 and enhanced by
knockdown of FOXA2. The transcription activity of the
hDIO1 promoter was also attenuated by simultaneous
knockdownofFOXA1andFOXA2 toan extent similar to
that seen for the knockdown of FOXA1. The suppressed
activity by knockdown of FOXA1 was not restored by
overexpression of USF, and the enhanced activity by
knockdown of FOXA2 was further enhanced by overex-
pression of USF. Thus, the response of the hDIO1 pro-









































FIG. 4. Effect of overexpression of FOXA2 or USF on hDIO1 promoter
activity. 187/4 hDIO1-Luc was transiently transfected into HepG2
cells in the presence of increasing amounts of vectors expressing
FOXA2 (F2) (A) or USF1 or USF2 (U1 and U2, respectively) (B). Promoter
activity was normalized to Renilla luciferase activity, then expressed as
the relative activity to 187/4 hDIO1-Luc cotransfected with pF4A
without a cDNA insert. Statistical significance was determined by












































































































FIG. 5. Knockdown of FOXA1 and/or FOXA2. Effect of transfection
of FOXA1 (A) and FOXA2 (B) siRNA on the mRNA expression level of
FOXA1, FOXA2, and D1. Simultaneous knockdown of FOXA1 and
FOXA2 (C) was performed using siRNA that has identical sequences in
both FOXA1 and FOXA2. N/C, Negative control siRNA; si-F1, siRNA
specific for FOXA1; si-F2, siRNA specific for FOXA2; si-F1/2, siRNA
specific for both FOXA1 and FOXA2. mRNA expression level was
normalized to that of cyclophilin A in each sample and expressed as
the relative activity to the basal expression (N/C). Statistical significance
was determined by unpaired t test. *, P  0.05; **, P  0.01. N.S.,
Not significant.
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moter to USF was greatly attenuated by knockdown of
FOXA1 and enhanced by knockdown of FOXA2. Fur-
thermore, we cotransfected a 187/4 hDIO1-Luc con-
struct and USF expression plasmids with or without a
FOXA2 expression plasmid into HepG2 cells. The tran-
scription activity of thehDIO1promoterwas enhanced in
the presence of transfected USF (Fig. 6C, white bar), but
the activitywas greatly attenuatedby cotransfectionof the
FOXA2expressionplasmid (Fig. 6C,blackbar). Thus, the
response of the hDIO1 promoter to USF was attenuated
by the coexpression of FOXA2. Collectively, these results
indicate that FOXA1 is required for the activation of the
hDIO1 promoter by USF and that FOXA2 represses the
transcription of hDIO1 and disrupts the interaction of
USF with FOXA1 by occupying the FOXA binding site.
Discussion
In this study, we analyzed the 5-upstream region of
hDIO1 to identify protein-DNA interactions within the
hDIO1 promoter. Our experiments demonstrated that
the region between nucleotides187 and132 is impor-
tant for hDIO1 promoter activity in HepG2 cells. We
identified functional elements for FOXA and USF within
this region, and we showed that these sites are important
for the transcriptional regulation of hDIO1. Recently,
Ohguchi et al. (9) identified aproximal hepatocyte nuclear
factor (HNF)4 binding site in mice, and they demon-
strated that the HNF4 binding site is essential for the
activation of the mouse D1 gene by HNF4. Deletion
analyses of the 5-flanking region of hDIO1 were per-
formed by Jakobs et al. (10) by transfecting 1.5- and
0.1-kb constructs into HepG2 cells, and they found that
both constructs substantially increased luciferase activity
compared with a promoterless vector. However, they did
not performahigher resolutionpromoter analysis, andwe
are the first to identify functional elements other than thy-
roid hormone responsive element in thehDIO1promoter.
The FOXAproteins were first identified as liver-enriched
factors because of their ability to bind the transthyretin gene
promoter, and they were originally termed HNF3 (11).
There are three FOXAproteins, FOXA1 (HNF3), FOXA2
(HNF3), andFOXA3 (HNF3),which are encodedbydif-
ferent genes ondifferent chromosomes (12). FOXAproteins
play important roles in early embryonic development and
organogenesis, and they are recognized as “pioneer factors”
(13). In addition, the FOXAproteins control glucosemetab-
olism through the regulation of multiple target genes in the
liver, pancreas, and adipose tissue after birth (13). Our
EMSAexperimentsdemonstrated thatFOXA1andFOXA2
specifically bound the identical FOXA binding site of the
hDIO1 promoter. Although all three FOXA proteins exist
relatively abundant in HepG2 cells (14) and recognize the
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FIG. 6. Interaction between FOXA and USF in the activation of the
hDIO1 promoter. A, Dependence of the activation of hDIO1 promoter
by USF on the FOXA binding site. Schematic diagram in the left of
figure representing WT and site-specific mutations of the hDIO1
promoter, introduced into the upstream region of the luciferase gene.
A cross represents the site-specific mutation of the putative FOXA
binding site. Each construct was transiently cotransfected into HepG2
cells in the presence of 5 ng of vectors expressing USF1 (U1) and/or
USF2 (U2). Promoter activity was normalized to Renilla luciferase
activity, then expressed as the relative activity to 187/4 hDIO1-Luc
cotransfected with pF4A without a cDNA insert. Statistical significance
was determined by ANOVA followed by Student-Newman-Keuls test.
**, P  0.01. B, Effect of knockdown of FOXA on the activation of the
hDIO1 promoter by USF. Short interfering RNA specific for FOXA1 and/
or FOXA2 or a negative control siRNA were transfected into HepG2
cells as described in Materials and Methods. One day after siRNA
transfection, 187/4 hDIO1-Luc was transiently cotransfected in the
presence of 5 ng of vectors expressing USF1 and/or USF2. N/C,
Negative control siRNA; si-F1, siRNA specific for FOXA1; si-F2, siRNA
specific for FOXA2; si-F1/2, siRNA specific for both FOXA1 and FOXA2.
Promoter activity was normalized to Renilla luciferase activity, then
expressed as the relative activity to 187/4 hDIO1-Luc cotransfected
with pF4A without a cDNA insert after knockdown by negative control
siRNA. Statistical significance was determined by ANOVA followed by
Student-Newman-Keuls test. **, P  0.01 relative to 187/4 hDIO1-
Luc cotransfected with pF4A without a cDNA insert after knockdown
by siRNA specific for FOXA2. C, Effect of overexpression of FOXA2 on
the activation of the hDIO1 promoter by USF. 187/4 hDIO1-Luc
was transiently transfected into HepG2 cells in the presence of 5 ng of
vectors expressing USF1 (U1), USF2 (U2), and/or FOXA2. Promoter
activity was normalized to Renilla luciferase activity, then expressed as
the relative activity to 187/4 hDIO1-Luc cotransfected with pF4A
without a cDNA insert. Statistical significance was determined by
ANOVA followed by Student-Newman-Keuls test. **, P  0.01. LUC,
Luciferase.
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ity and DNA binding capacity may account for their speci-
ficity (15). Indeed, there are very few reports that FOXA1
andFOXA2sharean identical binding site andcoparticipate
in the transcriptional regulation of a single gene (16). Our
transfection assays and siRNA experiments demonstrated
thathDIO1 ispositivelyregulatedbyFOXA1andnegatively
regulated by FOXA2 and that FOXA1 and FOXA2 interact
to coordinately regulate hDIO1 expression. These results
suggest thatFOXAproteinsare involved in thyroidhormone
homeostasis.
USF proteins were first identified as regulators of adeno-
virus major late promoter transcription (17, 18). There are
two USF proteins, 43 kDa (USF1) and 44 kDa (USF2), en-
coded by different genes on different chromosomes (19, 20).
USF proteins primarily bind as dimers to consensus se-
quences containing the CACGTG motif termed an E-box
(18, 19, 21). USF proteins are ubiquitously expressed, al-
though different ratios of USF homo- and heterodimers are
found in different cell types (22). The molecular details of
USFbindingandactivityhavebeenwell characterized,but its
biological role remainspoorlyunderstood.USFproteins reg-
ulate the expression of several genes related to glucose and
lipid metabolism and peptide hormone synthesis, including
liver-type pyruvate kinase (23) and glucokinase (24), fatty
acid synthase (25), apolipoprotein A-II (26), calcitonin/cal-
citonin gene-related peptide (27), and ghrelin (8). In our
study, we demonstrated that the putative E-box site in the
hDIO1 promoter specifically bound the USF1/USF2 het-
erodimer and that promoter activity increased in a dose-de-
pendent manner with the cotransfection of the USF1/2 ex-
pression plasmid. These results suggest that USF positively
regulate hDIO1 expression. Additionally, promoter activity
was almost completely abolished by mutation of the E-box
motif, indicating that USF proteins are critical for the tran-
scriptional regulation of hDIO1 and thyroid hormone ho-
meostasis in the liver and possibly kidney.
The response of the hDIO1 promoter to USFwas greatly
attenuated bymutation of the FOXAbinding site or knock-
down of FOXA1, indicating that
FOXA1isnecessary for the expressionof
hDIO1 by USF. FOXA1 plays an essen-
tial role in the “pioneering” of gene reg-
ulatory elements, allowing for the re-
cruitment of additional factors required
for gene regulation (28), and our data





our experimental condition (data not
shown), a direct physical interaction be-
tweenFOXA1andUSFhasbeen reported through theuseof
immunoprecipitation and glutathione S-transferase pull-
down assays (29). Furthermore, the cooperation between
FOXA1 and USF likely contributes to the liver-specific acti-
vation of hDIO1; although FOXA1 was expressed in both
HepG2 and TSA201 cells in our preliminary experiments
(data not shown), only HepG2 cells demonstrated substan-
tial differences in promoter activity by transfection of
187/4 hDIO1-Luc and mutation of the FOXA binding
site. Interactions between cell-specific factors and other reg-
ulatorsare thought tocontribute tothetissue-specificcontrol
of gene expression by the ubiquitous USF proteins (26, 30–
34), and Fig. 7 shows our working model for the regulation
of liver-specific expressionofhDIO1by transcription factor
bindingtothe187to132regionofthehDIO1promoter.
In this model, hDIO1 promoter activity is modulated by
FOXA1, FOXA2, andUSFproteins, and these transcription
factors interact with each other to fine-tune the hDIO1 pro-
moter activity.
In conclusion, we have shown that FOXA1, FOXA2,
and USF regulate hDIO1 expression in the liver. FOXA1
and FOXA2 both participate in the liver-specific regula-
tion of hDIO1 expression, and FOXA1 and USF act to-
gether to promote the liver-specific activation of hDIO1.
FOXA1 and FOXA2 are likely involved in thyroid hor-
mone homeostasis in the liver.
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